CureVac NV (CureVac NV) Debt-to-Equity : 0.08 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is CureVac NV Debt-to-Equity?

CureVac NV's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $5.46 Mil. CureVac NV's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $40.15 Mil. CureVac NV's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $563.73 Mil. CureVac NV's debt to equity for the quarter that ended in Dec. 2023 was 0.08.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for CureVac NV's Debt-to-Equity or its related term are showing as below:

CVAC' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.85 Med: 0.04 Max: 0.08
Current: 0.08

During the past 6 years, the highest Debt-to-Equity Ratio of CureVac NV was 0.08. The lowest was -1.85. And the median was 0.04.

CVAC's Debt-to-Equity is ranked better than
63.69% of 1074 companies
in the Biotechnology industry
Industry Median: 0.145 vs CVAC: 0.08

CureVac NV Debt-to-Equity Historical Data

The historical data trend for CureVac NV's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV Debt-to-Equity Chart

CureVac NV Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-1.85

0.04

0.08

CureVac NV Quarterly Data
	Dec18	Mar19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.08	0.06	0.06	0.07	0.08

Competitive Comparison of CureVac NV's Debt-to-Equity

For the Biotechnology subindustry, CureVac NV's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CureVac NV's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CureVac NV's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where CureVac NV's Debt-to-Equity falls into.

CureVac NV Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

CureVac NV's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.458	+	40.152)	/	563.731
	=	0.08

CureVac NV's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.458	+	40.152)	/	563.731
	=	0.08

CureVac NV (NAS:CVAC) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

CureVac NV Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of CureVac NV's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

CureVac NV (CureVac NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (NAS:CVAC) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

CVAC:Mexico 1CVAC:Italy 0A9E:UK 5CV:Germany CVAC:Austria

Address

Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076

Website

https://www.curevac.com

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.